Dear Editor, I want to congratulate Chang and their colleagues for their article [1] in which they investigated the association between metastatic free interval (MFI) and subsequent survival from newly diagnosed metastatic breast cancer (MBC) in a population-level US cohort. They reported that prolonged MFI greater than 10 years between initial breast cancer diagnosis and subsequent metastatic disease was found to be associated with improved recurrent MBC 5-year survival and decreased risk of breast cancer-specific mortality. However, the authors did not provide detailed information about the association of immunohistochemical receptor status between primary and recurrent metastatic tumors. A change of estrogen receptor, progesterone receptor, and HER2 status in recurrent metastatic tumors has frequently been reported. The actual incidence of this phenomenon has been debated. Recent meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases showed that negative to positive conversion percentages were 21.5%, 15.9%, and 9.5% for estrogen receptor, progesterone receptor, and HER2, respectively. In this study, the authors did not look at any association between discordant rate and MFI [2] . In conclusion, better pathological tumor characteristics might occur in recurrent MBC patients after 10-year MFI. This issue merits further investigation.
Dear Editor, I want to congratulate Chang and their colleagues for their article [1] in which they investigated the association between metastatic free interval (MFI) and subsequent survival from newly diagnosed metastatic breast cancer (MBC) in a population-level US cohort. They reported that prolonged MFI greater than 10 years between initial breast cancer diagnosis and subsequent metastatic disease was found to be associated with improved recurrent MBC 5-year survival and decreased risk of breast cancer-specific mortality. However, the authors did not provide detailed information about the association of immunohistochemical receptor status between primary and recurrent metastatic tumors. A change of estrogen receptor, progesterone receptor, and HER2 status in recurrent metastatic tumors has frequently been reported. The actual incidence of this phenomenon has been debated. Recent meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases showed that negative to positive conversion percentages were 21.5%, 15.9%, and 9.5% for estrogen receptor, progesterone receptor, and HER2, respectively. In this study, the authors did not look at any association between discordant rate and MFI [2] . In conclusion, better pathological tumor characteristics might occur in recurrent MBC patients after 10-year MFI. This issue merits further investigation.
